Browse Result
Total number of records for Allergic Rhinitis in Nasal Fluid of Human in DAAB (Version-2) database: 22
| Record no | Disease | Organism | Sample | Gene Name | Techniques | Omics | Study | Comments | Pubmed ID |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Allergic Rhinitis | Human | Nasal Fluid | ALB | LC-MS/MS and ELISA | Proteomics | High Throughput and Low Throughput | This protein is identified as s potential markers for treatment response to Glucocorticoids in allergic rhinitis. It is a component of acute phase response pathway. Its expression decrease following GC treatment as estimated in LC-MS/MS but not significantly in ELISA assay. | 21887273 |
| 2 | Seasonal Allergic Rhinitis patients treated with glucocorticoids for biomarker identification. | Human | Nasal Fluid | ORM1 | Quantitative proteomic analysis through LC/MSMS and ELISA | Proteomics | High Throughput and Low Throughput | ORM is a serum protein which is synthesised by the liver as well as Epithelial Cells and macrophages. It exerts immunomodulatory action during acute phase immune response and is significantly decreased after glucocorticoid treatment | 21887273 |
| 3 | Seasonal Allergic Rhinitis patients treated with glucocorticoids for biomarker identification. | Human | Nasal Fluid | ORM2 | Quantitative proteomic analysis through LC/MSMS and ELISA | Proteomics | High Throughput and Low Throughput | ORM is a serum protein which is synthesised by the liver as well as Epithelial Cells and macrophages. It exerts immunomodulatory action during acute phase immune response and is significantly decreased after glucocorticoid treatment | 21887273 |
| 4 | Seasonal Allergic Rhinitis patients treated with glucocorticoids for biomarker identification. | Human | Nasal Fluid | FGA | Quantitative proteomic analysis through LC/MSMS and ELISA | Proteomics | High Throughput and Low Throughput | Part of the acute phase response pathway and significantly decreased after Glucocorticoid treatment | 21887273 |
| 5 | Seasonal Allergic Rhinitis patients treated with glucocorticoids for biomarker identification. | Human | Nasal Fluid | APOH | Quantitative proteomic analysis through LC/MSMS and ELISA | Proteomics | High Throughput and Low Throughput | Part of the acute phase response pathway and significantly decreased after Glucocorticoid treatment | 21887273 |
| 6 | Seasonal Allergic Rhinitis patients treated with glucocorticoids for biomarker identification. | Human | Nasal Fluid | SERPINB3 | Quantitative proteomic analysis through LC/MSMS and ELISA | Proteomics | High Throughput and Low Throughput | Upregulated in Bronchial Epithelial Cells in asthma patients and significantly decreased after glucocorticoid treatment | 21887273 |
| 7 | Seasonal Allergic Rhinitis patients treated with glucocorticoids for biomarker identification. | Human | Nasal Fluid | A2M | Quantitative proteomic analysis through LC/MSMS and ELISA | Proteomics | High Throughput | Decreased after glucocorticoid treatment | 21887273 |
| 8 | Seasonal Allergic Rhinitis patients treated with glucocorticoids for biomarker identification. | Human | Nasal Fluid | APOA1 | Quantitative proteomic analysis through LC/MSMS and ELISA | Proteomics | High Throughput | Enriched in acute phase response pathway | 21887273 |
| 9 | Seasonal Allergic Rhinitis patients treated with glucocorticoids for biomarker identification. | Human | Nasal Fluid | C4B | Quantitative proteomic analysis through LC/MSMS and ELISA | Proteomics | High Throughput | Enriched in acute phase response pathway | 21887273 |
| 10 | Seasonal Allergic Rhinitis patients treated with glucocorticoids for biomarker identification. | Human | Nasal Fluid | C5 | Quantitative proteomic analysis through LC/MSMS and ELISA | Proteomics | High Throughput | Enriched in acute phase response pathway | 21887273 |
| 11 | Seasonal Allergic Rhinitis patients treated with glucocorticoids for biomarker identification. | Human | Nasal Fluid | C3 | Quantitative proteomic analysis through LC/MSMS and ELISA | Proteomics | High Throughput | Enriched in acute phase response pathway | 21887273 |
| 12 | Seasonal Allergic Rhinitis patients treated with glucocorticoids for biomarker identification. | Human | Nasal Fluid | CP | Quantitative proteomic analysis through LC/MSMS and ELISA | Proteomics | High Throughput | Enriched in acute phase response pathway | 21887273 |
| 13 | Seasonal Allergic Rhinitis patients treated with glucocorticoids for biomarker identification. | Human | Nasal Fluid | SCGB1D2 | Quantitative proteomic analysis through LC/MSMS and ELISA | Proteomics | High Throughput and Low Throughput | Decreased after Glucocorticoid treatment | 21887273 |
| 14 | Seasonal Allergic Rhinitis patients treated with glucocorticoids for biomarker identification. | Human | Nasal Fluid | FN1 | Quantitative proteomic analysis through LC/MSMS and ELISA | Proteomics | High Throughput | Enriched in acute phase response pathway | 21887273 |
| 15 | Seasonal Allergic Rhinitis patients treated with glucocorticoids for biomarker identification. | Human | Nasal Fluid | HPX | Quantitative proteomic analysis through LC/MSMS and ELISA | Proteomics | High Throughput | Enriched in acute phase response pathway | 21887273 |
| 16 | Seasonal Allergic Rhinitis patients treated with glucocorticoids for biomarker identification. | Human | Nasal Fluid | HRG | Quantitative proteomic analysis through LC/MSMS and ELISA | Proteomics | High Throughput | Decreased after glucocorticoid treatment | 21887273 |
| 17 | Seasonal Allergic Rhinitis patients treated with glucocorticoids for biomarker identification. | Human | Nasal Fluid | ITIH2 | Quantitative proteomic analysis through LC/MSMS and ELISA | Proteomics | High Throughput | Enriched in acute phase response pathway | 21887273 |
| 18 | Seasonal Allergic Rhinitis patients treated with glucocorticoids for biomarker identification. | Human | Nasal Fluid | SERPINA1 | Quantitative proteomic analysis through LC/MSMS and ELISA | Proteomics | High Throughput | Enriched in acute phase response pathway | 21887273 |
| 19 | Seasonal Allergic Rhinitis patients treated with glucocorticoids for biomarker identification. | Human | Nasal Fluid | SERPING1 | Quantitative proteomic analysis through LC/MSMS and ELISA | Proteomics | High Throughput | Enriched in acute phase response pathway | 21887273 |
| 20 | Seasonal Allergic Rhinitis patients treated with glucocorticoids for biomarker identification. | Human | Nasal Fluid | TF | Quantitative proteomic analysis through LC/MSMS and ELISA | Proteomics | High Throughput | Enriched in acute phase response pathway | 21887273 |
| 21 | Seasonal Allergic Rhinitis patients treated with glucocorticoids for biomarker identification. | Human | Nasal Fluid | CTSD | Quantitative proteomic analysis through LC/MSMS and ELISA | Proteomics | High Throughput and Low Throughput | Significantly decreased after glucocorticoid treatment | 21887273 |
| 22 | Seasonal Allergic Rhinitis | Human | Nasal Biopsy, Nasal Fluid | VEGFA | Microarray, ELISA | Genomics, Others | High Throughput, Low Throughput | VEGFA was up regulated in allergic rhinitis patients as compared to healthy controls. VEGFA level in nasal fluid was found to increase upon allergen challenge. Oligonucleotide microarray analysis of nasal biopsies and protein analyses of nasal fluids indicate that VEGFA may be an important mediator in Seasonal Allergic Rhinitis. | 12633568 |